How effective is talquetamab-tgvs?

The primary efficacy outcome measures were overall response rate and duration of response as assessed by an independent review committee usingIMWG criteria. The primary efficacy population consisted of participants who had received at least four prior therapies, including a proteasome inhibitor, an immunomodulator, and an antiCD38monoclonal antibody. The overall response rate for 100 participants receiving 0.4 mg/kg per week was 73% (95% confidence interval (CI): 63.2%, 81.4%), and the median duration of response was 9.5 months (95% CI: 6.5, not estimable). The overall response rate in 87 subjects who received 0.8 mg/kg every two weeks was 73.6% (95% CI: 63%, 82.4%), and the median duration of response was not estimable. An estimated 85%of responders maintained a response for at least 9 months. If you want to get more high-quality information, you can contact YaDE. YaDE will do its best to learn more about high-quality overseas drugs for you.